Alpine Immune Sciences Inc (ALPN)
64.47
0.00 (0.00%)
USD |
NASDAQ |
Apr 18, 13:49
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.226B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 765.4% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 54.75 |
| Price to Book Value | 12.89 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.33% |
Profile
| Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases. |
| URL | https://www.alpineimmunesciences.com |
| Investor Relations URL | http://ir.nivalis.com/ |
| HQ State/Province | Washington |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 18, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases. |
| URL | https://www.alpineimmunesciences.com |
| Investor Relations URL | http://ir.nivalis.com/ |
| HQ State/Province | Washington |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 18, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |